☆ 4.7 Review

Pharmacological approaches to pulmonary fibrosis following COVID-19

FRONTIERS IN PHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.
Article Respiratory System

Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study

Frederic Schlemmer et al.

Summary: This pragmatic study aimed to describe the clinical follow-up and respiratory recovery trajectories of survivors of severe-to-critical COVID-19, as well as identify factors influencing their health-related quality of life. The results showed that although pulmonary function and radiological abnormalities improved up to 1 year post-acute COVID-19, a high percentage of severe-to-critical disease survivors had significant lung sequelae and residual symptoms, warranting prolonged follow-up.

EUROPEAN RESPIRATORY JOURNAL (2023)

Add to Collection
Review Medicine, General & Internal

The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis

Lauren L. O'Mahoney et al.

Summary: This study systematically synthesized global evidence on the prevalence of persistent symptoms in a general post COVID-19 population. The findings show that regardless of hospitalization status, at least 45% of COVID-19 survivors experience unresolved symptoms for about 4 months. The current understanding of Long Covid is limited by heterogeneous study design, follow-up durations, and measurement methods, hindering effective treatment and management strategies.

ECLINICALMEDICINE (2023)

Add to Collection
Article Virology

An overview on the treatments and prevention against COVID-19

Yunes Panahi et al.

Summary: This article summarizes potential therapeutic agents, including antiviral agents, biologic agents, anti-inflammatory agents, and herbal agents, in the treatment of COVID-19. It also discusses various vaccine candidates and platforms being used for the development of COVID-19 vaccines.

VIROLOGY JOURNAL (2023)

Add to Collection
Article Multidisciplinary Sciences

Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome

Joseph A. Lewnard et al.

Summary: Expansion of the SARS-CoV-2 BA.4 and BA.5 Omicron subvariants in populations with prevalent immunity from prior infection and vaccination, and associated burden of severe COVID-19, has raised concerns about their epidemiologic characteristics, including immune escape and severe clinical outcomes. However, this study found that although BA.4/BA.5 is associated with increased risk of breakthrough infection, it is not associated with differential risk of emergency department presentation, hospital admission, or intensive care unit admission compared to BA.2.

NATURE COMMUNICATIONS (2023)

Add to Collection
Article Medicine, General & Internal

Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition

Yan Xie et al.

Summary: This cohort study found that treatment with nirmatrelvir within 5 days of a positive SARS-CoV-2 test result was associated with reduced risk of post-COVID-19 condition (PCC) in individuals with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe disease.

JAMA INTERNAL MEDICINE (2023)

Add to Collection
Article Critical Care Medicine

Residual Lung Abnormalities after COVID-19 Hospitalization Interim Analysis of the UKILD Post-COVID-19 Study

Iain Stewart et al.

Summary: This study analyzed the data from the UK Interstitial Lung Disease Consortium (UKILD) post-COVID-19 study to estimate the prevalence of residual lung abnormalities in hospitalized COVID-19 patients. The results showed that approximately 11% of recovered COVID-19 patients had residual lung abnormalities, highlighting the need for long-term monitoring.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Add to Collection
Review Microbiology

Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks

Filippo Patrucco et al.

Summary: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrosing disease where immune cells play a complex role in orchestrating the fibrosing response. Post-COVID pulmonary fibrosis (PCPF) is an emerging clinical entity that shares many similarities with IPF, including pathophysiological processes and response to treatments. SARS-CoV-2 infection can also cause acute exacerbation of IPF and negatively impact prognosis.

MICROORGANISMS (2023)

Add to Collection
Article Respiratory System

Novedades diagnósticas y terapéuticas en fibrosis pulmonar progresiva

María Molina-Molina et al.

ARCHIVOS DE BRONCONEUMOLOGIA (2022)

Add to Collection
Article Respiratory System

European Respiratory Society statement on long COVID follow-up

Katerina M. Antoniou et al.

Summary: This study summarizes the characteristics and impacts of follow-up care for long COVID patients in the 1-6 month period and finds limited evidence.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection
Letter Respiratory System

High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)

Sahajal Dhooria et al.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection
Article Respiratory System

Pneumomediastinum in COVID-19: a phenotype of severe COVID-19 pneumonitis? The results of the UK POETIC survey

James Melhorn et al.

Summary: This study aimed to determine the incidence of PTM in COVID-19 patients and identify factors associated with patient mortality. A total of 377 cases of COVID-19 PTM were identified during the study period, with an incidence of 0.64%. Mechanical ventilation was found to be the most important predictor of mortality in COVID-19 PTM patients.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection
Article Biology

Investigating phenotypes of pulmonary COVID-19 recovery: A longitudinal observational prospective multicenter trial

Thomas Sonnweber et al.

Summary: This study observed the respiratory and symptom recovery in COVID-19 patients during the follow-up period. The results showed that 49% of patients reported persistent symptoms at the 6-month follow-up. Structural lung abnormalities and impaired lung function were more common in severe cases. The study also found that early clinical indicators could predict the risk of incomplete pulmonary recovery.

ELIFE (2022)

Add to Collection
Review Biology

SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review

Indira R. Mendiola-Pastrana et al.

Summary: This systematic review analyzed the impact of different SARS-CoV-2 variants on clinical outcomes. The findings suggest that SARS-CoV-2 variants may be associated with mild to severe or even fatal clinical outcomes. Future studies should consider several covariates that influence the clinical course of the disease.

LIFE-BASEL (2022)

Add to Collection
Article Critical Care Medicine

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Ganesh Raghu et al.

Summary: This article provides updates on the guidelines for idiopathic pulmonary fibrosis (IPF) and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. The recommendations are based on consensus and systematic reviews, aiming to provide evidence-based guidance for clinicians.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Add to Collection
Article Radiology, Nuclear Medicine & Medical Imaging

Air trapping in COVID-19 patients following hospital discharge: retrospective evaluation with paired inspiratory/expiratory thin-section CT

Tomas Franquet et al.

Summary: The study reports the experience with paired inspiration/expiration thin-section CT scans in the follow-up of long-COVID patients with persistent respiratory symptoms. Thin-section CT findings commonly display air trapping in these patients, with predictors including gender and age.

EUROPEAN RADIOLOGY (2022)

Add to Collection
Article Respiratory System

Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection

Claudia Ravaglia et al.

Summary: This study analyzes the morphological and immunomolecular features of lung tissue in patients with post-COVID-19 lung disease. Different phenotypes with potentially different underlying pathogenic mechanisms have been identified, providing a better understanding of lung abnormalities after SARS-CoV-2 infection.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection
Article Respiratory System

Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial

Carlo Salvarani et al.

Summary: This study evaluated the efficacy and safety of pulse intravenous methylprednisolone in COVID-19 pneumonia patients, and found no significant benefit compared to standard treatment. There were no significant differences in hospital discharge time, survival rates, or overall mortality between the two groups, indicating limited effectiveness of pulse methylprednisolone therapy in treating COVID-19 pneumonia.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection
Review Medical Laboratory Technology

From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?

Jacob E. Michalski et al.

Summary: The COVID-19 pandemic has had a significant impact on the medical and scientific communities, and there is still much to learn about the chronic health burdens associated with this disease. The lungs are the primary site of infection and injury in COVID-19, leading to pneumonia and, in severe cases, acute respiratory distress syndrome (ARDS). This review aims to integrate our understanding of fibroproliferative ARDS with the current knowledge of the pulmonary consequences of COVID-19.

TRANSLATIONAL RESEARCH (2022)

Add to Collection
Review Respiratory System

Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis

Laura Fabbri et al.

Summary: This study assessed the proportion of lung disease in COVID-19 survivors by analyzing chest CT scans and pulmonary function tests. The findings suggest that pulmonary fibrosis and other sequelae are common in COVID-19 patients during follow-up. However, caution should be exercised in interpreting the estimates due to heterogeneity and differences in study populations.

THORAX (2022)

Add to Collection
Review Pharmacology & Pharmacy

Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review

Laura Bergantini et al.

Summary: The aim of this study was to systematically review the literature and identify the pathogenetic mechanisms involved in post-Covid-19 pulmonary fibrosis. The findings suggest the involvement of inflammatory cytokines, the renin-angiotensin system, galectin-3, and other factors in the development of pulmonary fibrosis.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection
Article Medicine, General & Internal

COVID-19 Autopsies Reveal Underreporting of SARS-CoV-2 Infection and Scarcity of Co-infections

Nathalie Schwab et al.

Summary: Autopsy results suggest that the mortality rate of COVID-19 may be higher than reported by clinicians, and most COVID-19 deaths are caused by the virus itself rather than coexisting conditions.

FRONTIERS IN MEDICINE (2022)

Add to Collection
Review Medicine, General & Internal

Post COVID-19 pulmonary fibrosis; a meta-analysis study

Bnar J. Hama Amin et al.

Summary: This meta-analysis study found that approximately 44.9% of COVID-19 survivors developed pulmonary fibrosis, and the severity of COVID-19 was significantly associated with the development of PCPF.

ANNALS OF MEDICINE AND SURGERY (2022)

Add to Collection
Review Respiratory System

How COVID-19 interacts with interstitial lung disease

Katherine J. Myall et al.

Summary: The global pandemic of COVID-19 has significantly affected patients with interstitial lung disease (ILD) in terms of diagnosis and management. Even in patients without prior lung disease, persistent lung damage and functional impairment can occur after infection. Therefore, the care model for ILD patients and those with persistent disease after recovering from COVID-19 needs to be explored.

BREATHE (2022)

Add to Collection
Review Biochemistry & Molecular Biology

Insights from Transcriptomics: CD1631 Profibrotic Lung Macrophages in COVID-19

Mallar Bhattacharya

Summary: COVID-19 lung macrophages play a significant role in fibrotic remodeling, but more research is needed to fully understand their function.

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2022)

Add to Collection
Editorial Material Respiratory System

Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

Nicolas Roche et al.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection
Article Medicine, General & Internal

COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis

Saptarshi Sinha et al.

Summary: There are fundamental similarities between COVID-19 and idiopathic pulmonary fibrosis (IPF), including gene expression patterns, cytokine storm, and AT2 cell cytopathic changes. Analysis of transcriptomic data and construction of protein-protein interaction networks suggest that COVID-19 may be driven by ER stress, resulting in AT2 cell arrest and immune cell pathology. These findings are important for the development of therapies for patients with IPF and other fibrotic interstitial lung diseases.

EBIOMEDICINE (2022)

Add to Collection
Editorial Material Medicine, General & Internal

What Covid Has Taught the World about Ethics

Ezekiel J. Emanuel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Review Immunology

Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals

Hayder M. Al-kuraishy et al.

Summary: Pirfenidone, an anti-fibrotic drug, has the potential to manage post-Covid-19 pulmonary fibrosis by inhibiting inflammatory cell accumulation, fibroblast proliferation, and extracellular matrix deposition. It also modulates signaling pathways involved in the pathogenesis of pulmonary fibrosis. Its anti-inflammatory and anti-fibrotic properties may attenuate post-Covid-19 pulmonary fibrosis.

INFLAMMOPHARMACOLOGY (2022)

Add to Collection
Editorial Material Health Care Sciences & Services

Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population

Ivan Cherrez-Ojeda et al.

Summary: This commentary highlights the major issues and possible solutions in managing post-COVID-19 pulmonary fibrosis in the Latin American region. There is currently limited evidence for successful long-term follow-up treatment for COVID-19. The lack of resources and multidisciplinary teams in Latin America exacerbates the lack of knowledge regarding proper treatment. Better infrastructure and well-designed studies are needed to develop scientific knowledge and improve treatment for the increasing prevalence of pulmonary fibrosis in Latin America.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection
Article Radiology, Nuclear Medicine & Medical Imaging

COVID-19 Vaccination reduced pneumonia severity

Noriaki Wada et al.

Summary: The aim of this study was to investigate the impact of vaccinations and boosters on the severity of COVID-19 pneumonia on CT scans during the period of Delta and Omicron variants. The results showed that vaccinated patients, with or without booster/additional vaccination, had milder COVID-19 pneumonia on CT scans than unvaccinated patients.

EUROPEAN JOURNAL OF RADIOLOGY OPEN (2022)

Add to Collection
Review Medicine, General & Internal

Post-COVID-19 Pulmonary Fibrosis

Asma Mohammadi et al.

Summary: SARS-CoV-2 infection can lead to acute respiratory distress syndrome (ARDS), resulting in pulmonary fibrosis and increased mortality. Anti-fibrotic drugs and lung transplant are potential treatment options. However, there is still a lack of knowledge in managing long-term sequelae, requiring further clinical trials and research.

CUREUS JOURNAL OF MEDICAL SCIENCE (2022)

Add to Collection
Letter Medicine, General & Internal

A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019

Fengqin Zhang et al.

CHINESE MEDICAL JOURNAL (2022)

Add to Collection
Article Health Care Sciences & Services

Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps

Hiroyasu Ino et al.

Summary: Drug repurposing in emergency situations raises issues of fairness in resource distribution, requiring careful consideration of social and ethical ramifications. Rapid accumulation of ethically and scientifically valid evidence, as well as obtaining information on resource quantity, is crucial in addressing these issues.

CAMBRIDGE QUARTERLY OF HEALTHCARE ETHICS (2021)

Add to Collection
Article Rheumatology

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Anna-Maria Hoffmann-Vold et al.

Summary: This study utilized data from the European Scleroderma Trials And Research (EUSTAR) database to analyze the disease course, progression patterns, and predictive factors for progressive interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD (SSc-ILD). The results showed that male sex, higher modified Rodnan skin score, and reflux/dysphagia symptoms were the strongest predictive factors for forced vital capacity (FVC) decline over a 5-year period in SSc-ILD patients.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection
Review Infectious Diseases

Azithromycin in the treatment of COVID-19: a review

Daniel Echeverria-Esnal et al.

Summary: Azithromycin shows antiviral and immunomodulatory properties, which may be beneficial in treating COVID-19. However, evidence for its use is scarce and of low quality.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)

Add to Collection
Article Cell Biology

Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID-19 pneumonia in Wuhan, China

Yan Li et al.

Summary: COVID-19 pneumonia patients who develop diffuse alveolar damage (DAD) can progress to the fibrosing pattern, with younger age and longer duration of illness, hospitalisation, and mechanical ventilation. Further studies are needed to determine the risk of developing pulmonary fibrosis in surviving patients.

HISTOPATHOLOGY (2021)

Add to Collection
Review Chemistry, Medicinal

Lung Fibrosis after COVID-19: Treatment Prospects

Evgeny Bazdyrev et al.

Summary: The ongoing battle against COVID-19 has revealed the significant impact of the disease on lung function, with a high incidence of impaired DLCO and persistent lung damage. Current efforts are focused on developing effective treatments for post-COVID lung fibrosis to address the long-term complications caused by the virus.

PHARMACEUTICALS (2021)

Add to Collection
Review Chemistry, Medicinal

Clinical Management of COVID-19: A Review of Pharmacological Treatment Options

Ashli M. Heustess et al.

Summary: Research on pharmacological treatments for COVID-19 has shown mixed data on efficacy and safety, with limited clinical experience with approved and repurposed drugs. The lack of standard treatment makes interpretation of results challenging. Continuous monitoring of the efficacy and safety of current COVID-19 therapeutics is necessary.

PHARMACEUTICALS (2021)

Add to Collection
Letter Infectious Diseases

The potential indicators for pulmonary fibrosis in survivors of severe COVID-19

Wenhui Huang et al.

JOURNAL OF INFECTION (2021)

Add to Collection
Article Pathology

Fibrotic progression and radiologic correlation in matched lung samples from COVID-19 post-mortems

Emanuela Barisione et al.

Summary: This study utilized an innovative cryobiopsy approach for post-mortem sampling of lung tissues from COVID-19 patients, demonstrating the progression of fibrosis over time and its correlation with computed tomography features. These findings may be helpful for accurate disease staging, with potential implications for treatment and patient follow-up.

VIRCHOWS ARCHIV (2021)

Add to Collection
Review Physiology

Healing after COVID-19: are survivors at risk for pulmonary fibrosis?

Lindsay T. McDonald

Summary: The novel SARS-CoV-2 coronavirus, responsible for COVID-19, was first reported in Wuhan, China, in December 2019, and the World Health Organization declared a pandemic by March 2020. Concerns have been raised about potential long-term effects of COVID-19 on respiratory health, but with limited data available, predictions on long-term outcomes remain speculative. Improved recognition of potential risk factors for fibrotic disease through studying previous coronavirus outbreaks is crucial in understanding the potential long-term implications of COVID-19.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2021)

Add to Collection
Letter Critical Care Medicine

High Prevalence of Pulmonary Sequelae at 3 Months after Hospital Discharge in Mechanically Ventilated Survivors of COVID-19

Rob J. J. van Gassel et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

Add to Collection
Article Respiratory System

Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study

Sabina A. Guler et al.

Summary: The Swiss COVID-19 lung study investigated pulmonary sequelae of COVID-19 in 113 survivors. Severe/critical COVID-19 was associated with significant functional and radiological abnormalities 4 months after infection, potentially due to small-airway and lung parenchymal disease. Systematic follow-up for survivors needs to be evaluated to optimize care for patients recovering from COVID-19.

EUROPEAN RESPIRATORY JOURNAL (2021)

Add to Collection
Article Radiology, Nuclear Medicine & Medical Imaging

Radiological perspective of COVID-19 pneumonia: The early features and progressive behaviour on high-resolution CT

Tetsuya Tsujikawa et al.

Summary: This pictorial essay examines the early features and potential progressive behavior of COVID-19 on HRCT of the lung, providing important clues for understanding the disease.

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2021)

Add to Collection
Article Radiology, Nuclear Medicine & Medical Imaging

Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia

Xiaoyu Han et al.

Summary: The study found that over one-third of severe COVID-19 patients showed fibrotic-like changes in the lung at 6-month follow-up CT, which were associated with older age, acute respiratory distress syndrome, longer hospital stays, tachycardia, noninvasive mechanical ventilation, and higher initial chest CT score.

RADIOLOGY (2021)

Add to Collection
Review Cardiac & Cardiovascular Systems

Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians

Sabrina Setembre Batah et al.

Summary: COVID-19 caused by SARS-CoV-2 is a global pandemic, with patients progressing from flu-like symptoms to severe acute lung injury characterized by acute and diffuse inflammatory damage to the alveolar-capillary barrier.

RESPIRATORY MEDICINE (2021)

Add to Collection
Article Multidisciplinary Sciences

Causes of death and comorbidities in hospitalized patients with COVID-19

Sefer Elezkurtaj et al.

Summary: The study conducted autopsies on 26 patients who died after SARS-CoV-2 infection and COVID-19, finding that septic shock and multi organ failure were the most common immediate causes of death, often due to suppurative pulmonary infection. Most patients had comorbidities such as hypertension, ischemic heart disease, and obesity. The majority of deaths were found to be directly related to COVID-19, with contributory implications of preexisting health conditions to the mechanism of death.

SCIENTIFIC REPORTS (2021)

Add to Collection
Article Medicine, General & Internal

Case Report: Nintedaninb May Accelerate Lung Recovery in Critical Coronavirus Disease 2019

Cecilia Bussolari et al.

Summary: The study administered nintedanib through compassionate use to three patients with COVID-19 pneumonia requiring ECMO support and found that the treatment led to rapid improvement in respiratory function and systemic inflammation, resulting in the withdrawal of ECMO support. Nintedanib was well-tolerated by the patients and may have a promising role in modulating lung inflammation and remodeling to promote lung repair in severe COVID-19 cases with delayed respiratory function recovery.

FRONTIERS IN MEDICINE (2021)

Add to Collection
Review Medicine, General & Internal

Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection A Systematic Review

Destin Groff et al.

Summary: This systematic review found that more than half of COVID-19 survivors experienced PASC 6 months after recovery, with the most common effects being functional mobility impairments, pulmonary abnormalities, and mental health disorders.

JAMA NETWORK OPEN (2021)

Add to Collection
Article Multidisciplinary Sciences

Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks

David T. Arnold et al.

Summary: The study found that high KL-6 levels at 12 weeks were associated with persisting CT abnormalities (GGO/fibrosis), suggesting a need for further exploration. KL-6 may help differentiate patients with persisting dyspnoea due to complications rather than deconditioning or dysfunctional breathing alone, posing an important future research question.

PLOS ONE (2021)

Add to Collection
Article Respiratory System

Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length

Claire F. McGroder et al.

Summary: Patients who underwent mechanical ventilation for severe COVID-19 are more likely to develop fibrotic-like radiographic abnormalities after hospitalisation. The severity of initial illness, duration of mechanical ventilation, lactate dehydrogenase on admission, and leucocyte telomere length are independent risk factors for these abnormalities, which are correlated with lung function, cough, and frailty measures, but not with dyspnoea.

THORAX (2021)

Add to Collection
Article Critical Care Medicine

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Juergen Behr et al.

Summary: This multicentre, double-blind, randomised, placebo-controlled trial aimed to evaluate the efficacy and safety of pirfenidone in patients with progressive fibrotic interstitial lung diseases. Results after 48 weeks showed a significantly lower decline in FVC % predicted in the pirfenidone group compared to placebo, suggesting that adding pirfenidone to existing treatment might attenuate disease progression in these patients.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection
Article Critical Care Medicine

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Xiaojun Wu et al.

Summary: Most patients recovering from severe COVID-19 showed improvement in dyspnoea scores and exercise capacity over time, but a subgroup of patients still exhibited persistent physiological and radiographic changes at 12 months post-discharge. A unified pathway for respiratory follow-up is needed for COVID-19 patients.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection
Review Respiratory System

Pulmonary fibrosis secondary to COVID-19: a narrative review

Suzana Erico Tanni et al.

Summary: There is limited understanding of the risk factors, histopathology, and pathophysiology of post-COVID-19 pulmonary fibrosis. Serial clinical screening for pulmonary fibrosis is recommended after COVID-19, and further research is needed to determine the risk factors and appropriate management of post-COVID-19 pulmonary fibrosis.

EXPERT REVIEW OF RESPIRATORY MEDICINE (2021)

Add to Collection
Review Public, Environmental & Occupational Health

Effective public health measures to mitigate the spread of COVID-19: a systematic review

Imen Ayouni et al.

Summary: This systematic review evaluated the effectiveness of various public health interventions, including travel restrictions, border measures, quarantine, city lockdowns, mass gathering restrictions, social distancing, mask wearing, contact tracing, testing, school closures, and personal protective equipment in mitigating the spread of COVID-19.

BMC PUBLIC HEALTH (2021)

Add to Collection
Review Immunology

COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts

Alison E. John et al.

Summary: The COVID-19 pandemic started in late 2019 in Wuhan City, China and has since spread worldwide. The disease, caused by the novel SARS-CoV-2 virus, primarily affects the respiratory system but can also impact other bodily systems. Patients may develop features of interstitial pulmonary fibrosis, raising questions about the long-term effects and progression of the disease.

IMMUNOLOGICAL REVIEWS (2021)

Add to Collection
Article Infectious Diseases

Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study

Yutaka Umemura et al.

Summary: The study aimed to investigate the efficacy and safety of nintedanib in COVID-19 patients with pulmonary fibrosis. Results indicated that nintedanib may offer potential benefits for minimizing lung injury in COVID-19.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies

Yu-Wen Zhou et al.

Summary: Due to limitations in current drug discovery efforts against SARS-CoV-2 and a lack of understanding of the biological mechanisms underlying COVID-19, alternative therapeutic targets are urgently needed. This study classified current COVID-19 therapeutic strategies into targeting the virus and targeting the host, focusing on repurposing drugs, emerging approaches, and promising potential targets.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection
Letter Critical Care Medicine

Pulmonary Fibrosis in COVID-19 Recovered Patients: Problem and Potential Management

Bhavana Kayarat et al.

INDIAN JOURNAL OF CRITICAL CARE MEDICINE (2021)

Add to Collection
Article Respiratory System

Persistent Post-COVID-19 Interstitial Lung Disease An Observational Study of Corticosteroid Treatment

Katherine Jane Myall et al.

Summary: Following SARS-CoV-2 infection, some patients develop persistent radiological inflammatory lung disease and functional deficits. Early treatment with corticosteroids is well tolerated and associated with rapid and significant improvement.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2021)

Add to Collection
Article Respiratory System

Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019

Hiroaki Ogata et al.

Summary: A 78-year-old Japanese woman without a smoking history suffered from severe COVID-19, requiring mechanical ventilation and developing pulmonary fibrosis. She was gradually able to improve her respiratory function with methylprednisolone and nintedanib treatment, but still needed oxygen therapy.

RESPIROLOGY CASE REPORTS (2021)

Add to Collection
Review Respiratory System

Post-COVID lung fibrosis: The tsunami that will follow the earthquake

Zarir F. Udwadia et al.

Summary: This article discusses potential pulmonary sequelae post-COVID-19, which may progress to serious conditions such as PC-ILD. It also introduces clinical, laboratory, and radiographic clues at presentation that could help predict future lung fibrosis development. Responsible use of antifibrotic drugs is discussed, along with the biological rationale and potential roles in specific patient groups.

LUNG INDIA (2021)

Add to Collection
Review Virology

Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19

Chi Zhang et al.

Summary: The article introduces the potential mechanism of pulmonary fibrosis caused by the COVID-19 virus and discusses the role of three signaling pathways related to fibrosis in the lungs. It also explores the potential therapeutic value of two drugs for COVID-19-induced pulmonary fibrosis.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection
Article Critical Care Medicine

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Toby M. Maher et al.

LANCET RESPIRATORY MEDICINE (2020)

Add to Collection
Article Critical Care Medicine

Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis

Richard J. Allen et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)

Add to Collection
Article Radiology, Nuclear Medicine & Medical Imaging

Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China

Yueying Pan et al.

EUROPEAN RADIOLOGY (2020)

Add to Collection
Editorial Material Critical Care Medicine

Basing Respiratory Management of COVID-19 on Physiological Principles

Martin J. Tobin

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)

Add to Collection
Review Radiology, Nuclear Medicine & Medical Imaging

Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review

Zheng Ye et al.

EUROPEAN RADIOLOGY (2020)

Add to Collection
Article Cell Biology

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

Thomas Menter et al.

HISTOPATHOLOGY (2020)

Add to Collection
Review Immunology

The many faces of the anti-COVID immune response

Santosha A. Vardhana et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

Add to Collection
Editorial Material Medicine, General & Internal

COVID-19 Deaths: Are We Sure It Is Pneumonia? Please, Autopsy, Autopsy, Autopsy!

Cristoforo Pomara et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection
Article Medicine, General & Internal

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Maximilian Ackermann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection
Article Pharmacology & Pharmacy

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?

Francesco Ferrara et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Add to Collection
Editorial Material Pharmacology & Pharmacy

The Post-Lockdown Era: What Is Next in Italy?

Cristoforo Pomara et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection
Article Critical Care Medicine

COVID-19 interstitial pneumonia: monitoring the clinical course in survivors

Ganesh Raghu et al.

Lancet Respiratory Medicine (2020)

Add to Collection
Review Medicine, General & Internal

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review

W. Joost Wiersinga et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection
Review Medicine, General & Internal

Clinical-Forensic Autopsy Findings to Defeat COVID-19 Disease: A Literature Review

Francesco Sessa et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection
Article Respiratory System

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

Maryam Edalatifard et al.

EUROPEAN RESPIRATORY JOURNAL (2020)

Add to Collection
Editorial Material Medicine, General & Internal

Management of post-acute covid-19 in primary care

Trisha Greenhalgh et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection
Letter Cardiac & Cardiovascular Systems

COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead

Francesco Gentile et al.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)

Add to Collection
Article Infectious Diseases

First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution

Maurizio Marvisi et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection
Review Medicine, General & Internal

Spectrum of Fibrotic Lung Diseases

Marlies Wijsenbeek et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection
Editorial Material Medicine, General & Internal

A living WHO guideline on drugs for covid-19

Francois Lamontagne et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection
Article Immunology

Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)

Daniel Gagiannis et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection
Article Medicine, General & Internal

Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused

Sachin Chaudhary et al.

FRONTIERS IN MEDICINE (2020)

Add to Collection
Letter Cell Biology

Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs

Jun Wu et al.

CELL PROLIFERATION (2020)

Add to Collection
Article Medicine, Research & Experimental

Pirfenidone: A novel hypothetical treatment for COVID-19

Soroush Seifirad

MEDICAL HYPOTHESES (2020)

Add to Collection
Article Cell & Tissue Engineering

Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study

Peixun Zhang et al.

BONE RESEARCH (2020)

Add to Collection
Letter Respiratory System

SARS-CoV-2-induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities

Antoni Torres et al.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2020)

Add to Collection
Review Medicine, Research & Experimental

Management of Fibrosing Interstitial Lung Diseases

Toby M. Maher et al.

ADVANCES IN THERAPY (2019)

Add to Collection
Review Respiratory System

The natural history of progressive fibrosing interstitial lung diseases

Martin Kolb et al.

RESPIRATORY RESEARCH (2019)

Add to Collection
Review Medicine, General & Internal

Idiopathic Pulmonary Fibrosis

David J. Lederer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection
Editorial Material Respiratory System

Pirfenidone in the kaleidoscope: reflecting mechanisms through different angles

Argyris Tzouvelekis et al.

EUROPEAN RESPIRATORY JOURNAL (2018)

Add to Collection
Review Respiratory System

Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence

Luca Richeldi et al.

EUROPEAN RESPIRATORY REVIEW (2018)

Add to Collection
Review Respiratory System

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

Lutz Wollin et al.

EUROPEAN RESPIRATORY JOURNAL (2015)

Add to Collection
Review Medicine, General & Internal

Signaling in fibrosis: TGF-beta, wNT, and YAP/TAZ converge

Bram Piersma et al.

FRONTIERS IN MEDICINE (2015)

Add to Collection
Article Medicine, General & Internal

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Talmadge E. King et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection
Article Critical Care Medicine

Quality of Life, Pulmonary Function, and Tomographic Scan Abnormalities After ARDS

Joan R. Masclans et al.

CHEST (2011)

Add to Collection
Article Medicine, General & Internal

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Paul W. Noble et al.

LANCET (2011)

Add to Collection
Article Respiratory System

The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

Jenny C. Ngai et al.

RESPIROLOGY (2010)

Add to Collection
Article Respiratory System

Viral infection and aging as cofactors for the development of pulmonary fibrosis

Payal K Naik et al.

Expert Review of Respiratory Medicine (2010)

Add to Collection
Article Pharmacology & Pharmacy

Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

Hisashi Oku et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2008)

Add to Collection
Article Pediatrics

Pulse Steroid Therapy

Aditi Sinha et al.

INDIAN JOURNAL OF PEDIATRICS (2008)

Add to Collection
Review Rheumatology

Glucocorticoids in the treatment of rheumatic diseases - An update on the mechanisms of action

F Buttgereit et al.

ARTHRITIS AND RHEUMATISM (2004)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.